Distinguish copper content and intended formulation
FDA's GHK-Cu safety discussion specifically concerns injectable routes. A topical ingredient description does not establish suitability for injection or for the spray listed alongside vials.
Documentation to request
Request the peptide/copper specification and finished-formulation documents. Evaluate copper content separately from total labeled mass.
Regulatory context: FDA: substance-specific safety concerns. Source reviewed . This source does not verify the identity, testing or availability of our catalog references.
Related guidance: Evidence review before expanding a clinic menu. These references support a review, not a treatment recommendation or supply authorization.